Proteomics for cancer drug design. (3rd August 2019)

• Record Type: Journal Article
• Authors: Haymond, Amanda; Davis, Justin B.; Espina, Virginia
• Is Part Of: Expert review of proteomics. Volume 16:Number 8(2019)
• Page Start: 647
• Page End: 664
• Publication Date: 2019-08-03
• Subjects: Biosimilar -- drug discovery -- hot spot -- mass spectrometry -- peptide -- protein-protein interaction -- reverse phase protein array -- validation -- cancer; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1080/14789450.2019.1650025
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Introduction : Signal transduction cascades drive cellular proliferation, apoptosis, immune, and survival pathways. Proteins have emerged as actionable drug targets because they are often dysregulated in cancer, due to underlying genetic mutations, or dysregulated signaling pathways. Cancer drug development relies on proteomic technologies to identify potential biomarkers, mechanisms-of-action, and to identify protein binding hot spots. Areas covered : Brief summaries of proteomic technologies for drug discovery include mass spectrometry, reverse phase protein arrays, chemoproteomics, and fragment based screening. Protein-protein interface mapping is presented as a promising method for peptide therapeutic development. The topic of biosimilar therapeutics is presented as an opportunity to apply proteomic technologies to this new class of cancer drug. Expert opinion : Proteomic technologies are indispensable for drug discovery. A suite of technologies including mass spectrometry, reverse phase protein arrays, and protein-protein interaction mapping provide complimentary information for drug development. These assays have matured into well controlled, robust technologies. Recent regulatory approval of biosimilar therapeutics provides another opportunity to decipher the molecular nuances of their unique mechanisms of action. The ability to identify previously hidden protein hot spots is expanding the gamut of potential drug targets. Proteomic profiling permits lead compound evaluation beyond the one drug, one target paradigm.